Keyphrases
Urinary Tract Infection
100%
Gram-negative Bacilli
100%
Antimicrobial Resistance Genes
100%
Colistin Resistance
100%
New Antimicrobials
100%
Virulence
100%
Carbapenems
100%
Pandrug-resistant
100%
Carbapenem-resistant Gram-negative Bacteria
75%
Resistance Factor
75%
Oman
75%
OXA-48
50%
Carbapenem Resistance
50%
Colistin-resistant Bacteria
50%
Bacteria-resistant
50%
Antimicrobial Resistance
50%
Antimicrobial Combinations
50%
Combination Therapy
50%
Antimicrobial
50%
Colistin
50%
Patient Management
50%
Acinetobacter Baumannii (A. baumannii)
25%
Etiquette
25%
Resistant Isolate
25%
Preventive Measures
25%
Synergistic Antibacterial
25%
Carbapenemases
25%
Local-regional
25%
Pseudomonas Aeruginosa (P. aeruginosa)
25%
PhoPQ
25%
Core Genome multilocus Sequence Typing (cgMLST)
25%
New Antibiotics
25%
Time-kill
25%
CTX-M
25%
Antimicrobial-resistant Bacteria
25%
Enterobacterales
25%
Checkerboard
25%
Post-antibiotic Era
25%
Antimicrobial Factors
25%
Profile Factors
25%
Fluoroquinolone Resistance
25%
Acinetobacter
25%
Resistant Strains
25%
Mortality Benefit
25%
MgrB
25%
Aminoglycosides
25%
Meropenem-vaborbactam
25%
Bacterial Infection
25%
Immediate Action
25%
Health Community
25%
Resistance Resistance
25%
Centers for Disease Control
25%
MLST Type
25%
Clonal Types
25%
Proactive Approach
25%
Carbapenem-resistant Enterobacteriaceae
25%
Antibiotic Resistance Determinants
25%
Colistin-resistant
25%
Polymyxin
25%
Aminoglycoside Resistance
25%
Virulence Factors
25%
Patient Mortality
25%
Carbapenem-resistant Bacteria
25%
Resistance Type
25%
Management Plan
25%
Evidence-based Prescribing
25%
Type Classes
25%
Disease Prevention
25%
Resistance Markers
25%
Patient Morbidity
25%
Klebsiella Pneumoniae (K. pneumoniae)
25%
Multidrug-resistant Organisms
25%
Control Measures
25%
In Vitro Synergy
25%
Cefiderocol
25%
Multidrug-resistant Pathogens
25%
Eravacycline
25%
Plazomicin
25%
Prospective Randomized Trial
25%
Public Health
25%
Difficult-to-treat
25%
Treatment Choice
25%
Clinical Profile
25%
In Vitro Study
25%
Whole Genome Sequencing
25%
Genome Analysis
25%
Global Concern
25%
Escherichia Coli
25%
Health Care Costs
25%
World Health Organization
25%
Pseudomonas
25%
Medical Health
25%
Genotype
25%
Clinical Data
25%
INIS
genes
100%
urinary tract
100%
drugs
100%
bacillus
100%
virulence
100%
bacteria
100%
antibiotics
42%
management
42%
in vitro
42%
oman
42%
patients
42%
therapy
28%
levels
28%
control
28%
mortality
28%
pseudomonas
28%
utilities
14%
hospitals
14%
maps
14%
diseases
14%
sequence analysis
14%
mutations
14%
pathogens
14%
communities
14%
data
14%
pneumonia
14%
escherichia coli
14%
strains
14%
antimicrobial agents
14%
optimization
14%
morbidity
14%
world health organization
14%
public health
14%
cost
14%
genotype
14%
Medicine and Dentistry
Carbapenem
100%
Urinary Tract Infection
100%
Antiinfective Agent
100%
Antibiotic Resistance
100%
Gram-Negative Bacteria
100%
Colistimethate
90%
In Vitro
30%
Aminoglycoside
20%
Combination Therapy
20%
Antibiotics
20%
Patient Care
20%
Pathogen
10%
Carbapenemase
10%
Meropenem
10%
Acinetobacter
10%
Eravacycline
10%
Pseudomonas
10%
Inosine Phosphate
10%
Polymyxin
10%
Carbapenem-Resistant Enterobacteriaceae
10%
Health Care Cost
10%
Vaborbactam
10%
Cefiderocol
10%
Plazomicin
10%
Public Health
10%
Proton Nuclear Magnetic Resonance
10%
Pseudomonas aeruginosa
10%
Sequence Analysis
10%
Acinetobacter Baumannii
10%
Protein Sequencing
10%
Multilocus Sequence Typing
10%
Escherichia coli
10%
Bacterial Infection
10%
Diseases
10%
Virulence Factor
10%
Quinolone Derivative
10%